- Subjects between 18 and 76 years of age.
- Subjects previously enrolled in study A7281006 who have completed the blinded 84 day
(12 week) induction period or in study A7281008 who have completed Week 12 and have
demonstrated a clinical response as defined by that protocol.
- Subjects that have completed Day 84 (Week 12) of a PF-00547659 study but have
experienced serious event(s) related to the investigational product, an unstable
medical condition, or any other reason, in the opinion of the investigator, would
hinder entry or participation in this study.
- Subjects who are taking any dose of azathioprine, 6-mercaptopurine or methotrexate.